Listed by the USPTO as VAN DRUFF, SYDNEY
Tech Center 1600 • Art Units: 1643
This examiner grants 55% of resolved cases
VAN DRUFF, SYDNEY has 152 resolved cases in tech center 1600 and art unit 1643. The allowance rate is 55.3%, the interview lift is 32.0%, and the median time to allowance is 1155 days. The record shows allowance in a modest majority of resolved matters. Interviews are associated with a meaningful improvement relative to that outcome, while the median indicates prosecution that can extend beyond three years.
The principal companies are Novartis AG, AbbVie Inc., and Genentech Inc. The leading firms are Adams & Reese LH, ARENTFOX SCHIFF LLP, and Bennett Jones LLP. Counsel may want to prepare carefully for examiner interviews while maintaining a response plan capable of handling a prolonged biotechnology prosecution cycle.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18044405 | GALACTOSYLATED DENDRIMERS FOR TARGETED INTRACELLULAR DELIVERY TO HEPATOCYTES | Non-Final OA | The Johns Hopkins University |
| 17775198 | IDENTIFICATION OF SPLICING-DERIVED ANTIGENS FOR TREATING CANCER | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy55.3% of resolved applications examined by Sydney Van Druff were allowed (152 resolved cases), compared with 41.5% across Art Unit 1643 over the last five years.
This examiner's interview lift is +32.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Sydney Van Druff took 1,155 days on average from filing to allowance.
Sydney Van Druff examines applications in Art Unit 1643 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
